quinolinic acid has been researched along with minocycline in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bezard, E; Diguet, E; Gross, CE; Stefanova, N; Tison, F; Wenning, GK | 1 |
| Bantubungi, K; Blum, D; Brotchi, J; Brouillet, E; Chtarto, A; Déglon, N; Galas, MC; Greco, A; Jacquard, C; Levivier, M; Minghetti, L; Pintor, A; Popoli, P; Schiffmann, SN; Tai, K; Tenenbaum, L | 1 |
| Choi, HB; McLarnon, JG; Ryu, JK | 1 |
| Aguado, T; Azcoitia, I; Benito, C; Carrasco, C; Fernández-Ruiz, J; Galve-Roperh, I; Guzmán, M; Julien, B; Palazuelos, J; Pazos, MR; Resel, E; Romero, J; Sagredo, O | 1 |
| Chaudhary, T; Kumar, A; Mishra, J | 1 |
| Bahrami, Z; Firouzi, M; Harirchian, MH; Hashemi-Monfared, A; Zahednasab, H | 1 |
6 other study(ies) available for quinolinic acid and minocycline
| Article | Year |
|---|---|
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Microglia; Minocycline; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Primates; Quinolinic Acid; Rats; Rats, Wistar; Substantia Nigra; Treatment Failure | 2004 |
Minocycline in phenotypic models of Huntington's disease.
Topics: Animals; Calpain; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalitis; Glutamic Acid; Huntingtin Protein; Huntington Disease; Male; Minocycline; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Nitro Compounds; Nuclear Proteins; Phenotype; Propionates; Quinolinic Acid; Rats; Rats, Inbred Lew; Rats, Wistar; Staurosporine | 2005 |
Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Death; Cyclooxygenase 2; Disease Models, Animal; Drug Synergism; Huntington Disease; Immunohistochemistry; Inflammation; Male; Minocycline; Nerve Tissue Proteins; Neurons; Nitric Oxide Synthase Type II; Oxidative Stress; Pyruvic Acid; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2006 |
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Corpus Striatum; Humans; Huntingtin Protein; Huntington Disease; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Minocycline; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Quinolinic Acid; Receptor, Cannabinoid, CB2; Rotarod Performance Test; Seizures | 2009 |
Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences.
Topics: Animals; Behavior, Animal; Brain; Caspase 3; Disease Models, Animal; Drug Synergism; Electron Transport Complex IV; Glutathione; Hesperidin; Huntington Disease; Male; Maze Learning; Minocycline; Motor Activity; Neuroprotective Agents; Nitrites; Quinolinic Acid; Quinone Reductases; Rats; Rats, Wistar; Succinate Dehydrogenase; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2013 |
The effect of minocycline on indolamine 2, 3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia.
Topics: Animals; Brain; Cell Survival; Cells, Cultured; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Kynurenic Acid; Lipopolysaccharides; Microglia; Minocycline; Neuroglia; Quinolinic Acid; Rats; Rats, Wistar | 2018 |